All In Biotech

Drug Trial Radar · NCT00913744

Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion

A Randomized, Sham-Injection Controlled, Double-Masked, Multicenter Trial of Ocriplasmin Intravitreal Injection for Treatment of Focal Vitreomacular Adhesion in Subjects With Exudative Age-Related Macular Degeneration (AMD)

Last checked: Nov 20, 2026Latest source record: Dec 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Jan 2010

Primary completion

Dec 2012

Study completion Apr 2013

Sponsor

Lead sponsor
ThromboGenicsIndustry
Sponsor type
Industry
First posted
Jun 4, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in subjects diagnosed with exudative AMD with focal vitreomacular adhesion. Ultimately, it is believed that intravitreal ocriplasmin may offer physicians a safe agent for pharmacologic vitreolysis and nonsurgical resolution of focal vitreomacular adhesion in AMD subjects where this adhesion may be causally associated with worse prognosis).

Conditions

  • Exudative Age-Related Macular Degeneration
  • Focal Vitreomacular Adhesion

Interventions

  • OcriplasminDrug

    ocriplasmin intravitreal injection (125 µg)

  • Sham injectionDrug

    Sham injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects With Focal Vitreomacular Adhesion (VMA) Release by Day 28Time frame: Day 28

Locations

27 sites in 6 countries. Site status is shown where the registry gives one.

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • Retinal Consultants Medical Group

    Sacramento, California

  • University of Colorado Denver

    Aurora, Colorado

  • Center for Retina and Maculla Disease

    Winter Haven, Florida

  • Southeast Retina Center, PC

    Augusta, Georgia

  • VitreoRetinal Surgery, PA

    Minneapolis, Minnesota

  • Retina-Vitreous Center, PA

    New Brunswick, New Jersey

  • Allegheny Ophthalmic & Orbital Associates, PC

    Pittsburgh, Pennsylvania

  • Black Hills Regional Eye Institute

    Rapid City, South Dakota

  • Southeastern Retina Associates

    Kingsport, Tennessee

  • Retinal Consultants of Houston,

    Houston, Texas

  • Valley Retina Institute

    McAllen, Texas

  • U.Z. Leuven St. Rafaël Hospital

    Leuven, Belgium

  • Rabelais Ophthalmologic Center

    Lyon, France

  • Centre Paradis-Monticelli

    Marseille, France

  • Centre Ophtalmologique d'Imagerie et de Laser

    Paris, France

  • Centre Ophtalmologique de L'Odeon

    Paris, France

  • Universität Bonn Augenklinik

    Bonn, Germany

  • Universität Lübeck Universitätsklinikum Schleswig-Holstein

    Lübeck, Germany

  • Klinik für Augenheilkunde, Universitätsklinikum Gießen, Standort Marburg

    Marburg, Germany

  • Augenklinik der Ludwig Maximilians Universität München

    München, Germany

  • University of Milan Department of Clinical Science "Luigi Sacco"

    Milan, Italy

  • Largo Agostino Gemelli (University Hospital) Institute of Ophthalmology

    Rome, Italy

  • Royal Liverpool & Broadgreen Hospital

    Liverpool, United Kingdom

  • Moorfields Eye Hospital

    London, United Kingdom

  • Wolverhampton Eye Infirmary New Cross Hospital

    Wolverhampton, United Kingdom

  • Frimley Park Hospital

    Frimley, Camberley, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.